Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae

International Journal of Antimicrobial Agents

Volumn 51, Issue 4, 2018, Pages 629-635

  Santevecchi, Barbara A ^a,b,d   Smith, Tiffeny T ^a,c   MacVane, Shawn H ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d LEVINE CANCER INSTITUTE   (United States)

Author keywords

Antibiotic resistance; Carbapenem resistant Enterobacteriaceae; Ceftazidime avibactam; Gram negative organisms; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ABDOMINAL INFECTION; ACHROMOBACTER XYLOSOXIDANS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CASE STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL EXAMINATION; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL MORTALITY; HUMAN; INFORMATION PROCESSING; KLEBSIELLA PNEUMONIAE; MALE; MEDICAL RECORD REVIEW; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SKIN INFECTION; SOFT TISSUE INFECTION; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; TREATMENT OUTCOME; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PNEUMONIA; PSEUDOMONAS INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS;

EID: 85043285730     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.01.016     Document Type: Article

References (17)

1. Zasowski, E.J., Rybak, J.M., Rybak, M.J., The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy 35 (2015), 755–770.
2. Antibiotic resistance threats in the United States, 2013. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention; Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf, 2013. (Accessed 1 December 2016)
3. Centers for Disease Control and Prevention (CDC), Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62 (2013), 165–170.
4. Shields, R.K., Potoski, B.A., Haidar, G., Hao, B., Doi, Y., Chen, L., et al. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63 (2016), 1615–1618.
5. Temkin, E., Torre-Cisneros, J., Beovic, B., Benito, N., Giannella, M., Gilarranz, R., et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program. Antimicrob Agents Chemother, 61, 2017 pii: e01964-16.
6. King, M., Heil, E., Kuriakose, S., Bias, T., Huang, V., El-Beyrouty, C., et al. Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections: a multi-center study. Antimicrob Agents Chemother, 2017 Epub ahead of print.
7. Krapp, F., Grant, J.L., Sutton, S.H., Ozer, E.A., Barr, V.O., Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterization. Int J Antimicrob Agents 22 (2017), 1–4.
8. Lucasti, C., Popescu, I., Ramesh, M.K., Lipka, J., Sable, C., Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 68 (2013), 1183–1192.
9. Vazquez, J.A., Gonzalez Patzan, L.D., Stricklin, D., Duttaroy, D.D., Kreidly, Z., Lipka, J., et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28 (2012), 1921–1931.
10. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
11. Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 (2011), e56–e93.
12. Khwaja, A., KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 12 (2012), 1–138.
13. Avycaz (ceftazidime and avibactam), 2017, Allergan USA, Inc., Irvine (CA) Package insert.
14. Clinical Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement (M100-S26). 2016, CLSI, Wayne (PA).
15. Vincent, J.L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on ‘sepsis-related problems’ of the European Society of Intensive Care Medicine. Crit Care Med 26 (1998), 1793–1800.
16. Vasilevskis, E.E., Pandharipande, P.P., Graves, A.J., Shintani, A., Tsuruta, R., Ely, E.W., et al. Validity of a modified sequential organ failure assessment score using the Richmond Agitation-Sedation Scale. Crit Care Med 44 (2016), 138–146.
17. Santevecchi B.A., Steed L.L., Bosso J.A. Determination of carbapenem resistant Enterobacteriaceae resistance mechanisms. Poster presented at: The 20th Annual MAD-ID Meeting; May 11, 2017; Orlando, FL.